# NM_000186.4(CFH):c.2767C>T (p.Pro923Ser)

https://sugi.bio/variant/cfh-p-pro923ser

## Summary

**CFH p.Pro923Ser (c.2767C>T)** is classified **Uncertain significance** in CFH (ClinVar, Multiple submitters, 2 submitters; last evaluated 2024-04-20). AlphaMissense: likely benign (0.1108); Very rare (popmax 0.00935%, afr); Associated with basal laminar drusen.

**At a glance:** Uncertain significance · review: Multiple submitters · rsID rs368846503 · 2 submitters · 4 linked conditions · AlphaMissense likely benign · very rare (popmax 0.00935%, afr)

## For patients & families {#patients}

This is a change in the CFH gene that is currently of uncertain significance — a definitive interpretation has not yet been established, submitted by 2 submitters, and is linked to basal laminar drusen.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0015060/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [CFH](https://sugi.bio/atlas/gene/CFH/) |
| Protein change (HGVS p.) | p.Pro923Ser |
| Coding change (HGVS c.) | c.2767C>T |
| MANE Select transcript | [NM_000186](https://www.ncbi.nlm.nih.gov/nuccore/NM_000186) |
| dbSNP | [rs368846503](https://www.ncbi.nlm.nih.gov/snp/rs368846503/) |
| Variant type | single nucleotide variant |
| Location | chr1:196737645-196737645 (GRCh38) |
| ClinVar | [VCV1444110](https://www.ncbi.nlm.nih.gov/clinvar/variation/1444110/) |

**All HGVS expressions:** `LRG_47:g.90635C>T`, `NC_000001.10:g.196706775C>T`, `NC_000001.11:g.196737645C>T`, `NG_007259.1:g.90635C>T`, `NM_000186.4:c.2767C>T`

## Computational & population evidence {#evidence}

**Concordance:** ClinVar classifies this **uncertain**; the computational predictors unanimously lean **tolerated** — a triage signal, not a reclassification.

- AlphaMissense **likely benign** (0.1108)
- REVEL 0.283 (benign-leaning) — agrees with AlphaMissense
- SaProt LLR -6.667 (tolerated) — agrees with AlphaMissense
- → **In-silico consensus:** AlphaMissense, REVEL and SaProt all call this tolerated
- Conservation: phyloP -2.024, GERP -0.158 — fast-evolving / accelerated position
- CADD: **PHRED 17.26**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- Regional missense constraint: **o/e 1.01** across the covering region of the MANE Select transcript (196,690,101–196,743,557), spanning 53,456 bp. Chi-square p 0.76. Describes the region, not this allele; gnomAD v4.1.1's own constrained determination. *Descriptive; no ACMG code applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **0.00935%** (afr) · FAF95 0.00438% · FAF99 0.00309% · 7/74,876 in the highest group · 8/1,613,126 alleles overall — very rare (popmax 0.00935%, afr).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| African / African-American (grpmax) | 0.00935% | 10,697 |
| European (non-Finnish) | 8.48e-05% | 1,179,473 |

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**CFH** population constraint: LOEUF 0.43, pLI 0.99998, missense-Z 1.4706. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **C3 glomerulonephritis** — Definitive (AR)
- **atypical hemolytic-uremic syndrome** — Definitive (SD)

## Protein context {#protein}

Residue **923** lies in the sushi 15 domain; a disulfide bond.

AlphaFold model confidence (whole protein): pLDDT 78.54, 1% of residues very-high.

**51 experimental structure(s)** (PDB): [1HAQ](https://www.rcsb.org/structure/1HAQ), [1HCC](https://www.rcsb.org/structure/1HCC), [1HFH](https://www.rcsb.org/structure/1HFH), [1HFI](https://www.rcsb.org/structure/1HFI), [2BZM](https://www.rcsb.org/structure/2BZM), [2G7I](https://www.rcsb.org/structure/2G7I) — incl. mutant structure 2UWN.

## What this gene does {#gene-function}

*Describes the biological roles of CFH (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** CFH's established molecular role includes heparin binding. p.Pro923Ser falls in the sushi 15 domain.


### Pathways affected {#pathways}

CFH participates in **1 Reactome pathway** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [Regulation of Complement cascade](https://reactome.org/content/detail/R-HSA-977606) | curated |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** heparin binding, identical protein binding, heparan sulfate proteoglycan binding.

**Biological process:** proteolysis, inflammatory response, complement activation, complement activation, alternative pathway, central nervous system myelination, regulation of complement activation.

## Clinical significance {#significance}

**Uncertain significance** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2024-04-20.

**Submitter consensus:** unanimous (2/2 Uncertain significance).

**Submission history:** 2 submissions (2022–2024); classifications have been stable.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Fulgent Genetics, Fulgent Genetics | Uncertain significance | criteria provided, single submitter | clinical testing | 2024-04-20 |
| Labcorp Genetics (formerly Invitae), Labcorp | Uncertain significance | criteria provided, single submitter | clinical testing | 2022-08-10 |

## Associated conditions {#conditions}

[basal laminar drusen](https://sugi.bio/atlas/disease/basal-laminar-drusen/), [hemolytic uremic syndrome, atypical, susceptibility to, 1](https://sugi.bio/atlas/disease/hemolytic-uremic-syndrome-atypical-susceptibility-to-1/), [complement factor H deficiency](https://sugi.bio/atlas/disease/complement-factor-h-deficiency/), [age related macular degeneration 4](https://sugi.bio/atlas/disease/age-related-macular-degeneration-4/).

**Reported phenotype names (ClinVar):** Basal laminar drusen, not provided, Age related macular degeneration 4, Factor H deficiency, Hemolytic uremic syndrome, atypical, susceptibility to, 1, DRUSEN OF BRUCH MEMBRANE, DRUSEN, CUTICULAR, DRUSEN, EARLY ADULT-ONSET, GROUPED, COMPLEMENT FACTOR H DEFICIENCY, CFH DEFICIENCY.

## Similar variants {#similar}

Related CFH variant pages (same residue, condition, or type): [CFH c.1337-2A>G](/variant/cfh-c-1337-minus-2a-g), [CFH c.2236+1G>C](/variant/cfh-c-2236-plus-1g-c), [CFH c.350+1G>T](/variant/cfh-c-350-plus-1g-t), [CFH c.619+1G>A](/variant/cfh-c-619-plus-1g-a), [CFH p.Arg1215Ter](/variant/cfh-p-arg1215ter), [CFH p.Arg232Ter](/variant/cfh-p-arg232ter), [CFH p.Arg53Cys](/variant/cfh-p-arg53cys), [CFH p.Cys431Ser](/variant/cfh-p-cys431ser).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-11); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-07-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 1444110). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*